Business
REMINDER - International Cannabis Applauds the Selection of Wayland as One of Three Groups, Pending Review Period, for German Cannabis Production Licenses
VANCOUVER, British Columbia, April 05, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC:WLDCF) ("ICC" or "International
About this update from World Acceptance Corporation
[{"type":"text","content":"VANCOUVER, British Columbia, April 05, 2019 (GLOBE NEWSWIRE) -- ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC:WLDCF) (\"ICC\" or \"International Cannabis\" or the \"Company\") applauds Wayland Group Corp.'s (CSE: WAYL)(FWB: 75M)(OTCQB: MRRCF) (\"Wayland\") recent announcement regarding their selection by the German Federal Institute for Drugs and Medical Devices (\"BfArM\"), through its German joint venture Demecan GmbH, to begin domestic production of medical cannabis for the rapidly growing German patient population.Wayland is one of three groups that have been selected and is subject to a review period, after which a final decision will be made no earlier than April 17, 2019.Eugene Beukman, Chief Executive Officer and a Director of International Cannabis stated: \"Wayland's first mover advantage coupled with their surgical execution and best-in-class operations within the German cannabis market are further validated by this recent announcement. Wayland had the corporate foresight to identify Germany, early on, as one of the world's most exciting medical cannabis markets due to its progressive regulations, geometrically growing patient population, and insurance coverage for over 60 per cent of prescriptions. ICC enthusiastically applauds Wayland's selection by the BfArM, through its German joint venture Demecan GmbH, to begin domestic production of medical cannabis.\"As per the Company's previously announced Letter of Intent (\"LOI\") with Wayland to acquire 49.9 per cent of Wayland Group Corp.'s international assets and licence portfolio. Upon closing of the transaction, Wayland's international assets and licences will be transferred to a subsidiary, owned by Wayland and International Cannabis, 50.1 per cent and 49.9 per cent, respectively. The international subsidiary will include key management, pharmaceutical professionals and operations personnel from Wayland.ABOUT INTERNATIONAL CANNABISICC International Cannabis, through its subsidiaries, has operating assets and is developing a world-class platform for cultivation, extraction, formulation and distribution across the globe in the United Kingdom, Denmark, Poland, Switzerland, Germany, Macedonia, Bulgaria, Serbia, Croatia, Greece, Italy, Portugal, Malta, Colombia, Argentina, Australia, South Africa and Lesotho.ON BEHALF OF THE ICC INTERNATIONAL CANNABIS COR...